fingolimod hydrochloride has been researched along with Complications, Pregnancy in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Ariño, H; Baños, N; Blanco, Y; Llufriu, S; Martinez-Hernandez, E; Martinez-Lapiscina, EH; Montejo, C; Pulido-Valdeolivas, I; Reyes, D; Saiz, A; Sepúlveda, M; Sola-Valls, N; Zubizarreta, I | 1 |
| Arlauskienė, A; Laužikienė, D; Ramašauskaitė, D; Varytė, G; Zakarevičienė, J | 1 |
| Azami, S; Konoeda, F; Sato, H | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T; Meinl, I | 1 |
| Navardi, S; Sahraian, MA | 1 |
| Baghbanian, SM; Cheraghmakani, H; Nasehi, MM | 1 |
| Berenguer-Ruiz, L; Gimenez-Martinez, J; Palazón-Bru, A; Sempere, AP | 1 |
| Berenguer-Ruiz, L; Feliu-Rey, E; Sempere, AP | 1 |
| Langer-Gould, AM | 1 |
| Cohen, JA; Collins, W; Francis, G; Heining, P; Kappos, L; Karlsson, G; Koren, G; Zhang, X | 1 |
| Aguilera, C; Tintoré, M; Tur, C | 1 |
1 review(s) available for fingolimod hydrochloride and Complications, Pregnancy
| Article | Year |
|---|---|
Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy's Impact on Disease Activity.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Crotonates; Dimethyl Fumarate; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Hydroxybutyrates; Interferon-beta; Multiple Sclerosis; Natalizumab; Nitriles; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Prospective Studies; Rituximab; Toluidines | 2020 |
10 other study(ies) available for fingolimod hydrochloride and Complications, Pregnancy
| Article | Year |
|---|---|
Rebound of multiple sclerosis activity after fingolimod withdrawal due to planning pregnancy: Analysis of predisposing factors.
Topics: Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Live Birth; Lymphocytes; Magnetic Resonance Imaging; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Reproductive Behavior; Retrospective Studies; Severity of Illness Index; Symptom Flare Up; Time Factors | 2020 |
[A patient with relapsing-remitting multiple sclerosis who relapsed frequently and developed primary biliary cholangitis after pregnancy and discontinuation of fingolimod].
Topics: Adult; Autoantibodies; Biomarkers; Diagnosis, Differential; Female; Fingolimod Hydrochloride; Humans; Liver Cirrhosis, Biliary; Magnetic Resonance Imaging; Mitochondria; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Recurrence; Withholding Treatment | 2021 |
Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Recurrence | 2018 |
A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
Topics: Dextrocardia; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Pregnancy, Unplanned | 2018 |
Neurodevelopmental retardation in a baby born to a multiple sclerosis patient being treated with fingolimod.
Topics: Child, Preschool; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Infant, Newborn; Intellectual Disability; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Prenatal Exposure Delayed Effects | 2019 |
Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.
Topics: Adult; Disease Progression; Female; Fingolimod Hydrochloride; Follow-Up Studies; Glatiramer Acetate; Humans; Immunologic Factors; Interferon-beta; Multiple Sclerosis; Natalizumab; Pregnancy; Pregnancy Complications; Puerperal Disorders; Recurrence; Reproductive Behavior | 2019 |
Rebound of disease activity during pregnancy after withdrawal of fingolimod.
Topics: Adult; Anti-Inflammatory Agents; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Propylene Glycols; Sphingosine | 2013 |
The pill times 2: what every woman with multiple sclerosis should know.
Topics: Abnormalities, Drug-Induced; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Propylene Glycols; Sphingosine | 2014 |
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Middle Aged; Multiple Sclerosis; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Propylene Glycols; Sphingosine | 2014 |
[Disease modifying drugs in multiple sclerosis and pregnancy].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antibodies, Monoclonal, Humanized; Female; Fingolimod Hydrochloride; Glatiramer Acetate; Humans; Immunologic Factors; Immunosuppressive Agents; Infant, Newborn; Interferon-beta; Multiple Sclerosis; Natalizumab; Peptides; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Propylene Glycols; Sphingosine; Stillbirth | 2012 |